Skip to main content

Table 1 Baseline data

From: Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis

Study

Gender(M/F)

Age

N

Treatment

Duration (weeks)

Outcomes

Rosenstock, et al. (2021) [17]

56/59

53.6 ± 12.8

115

Placebo

40

HbA1c,Weight,AE, SAE

56/65

54.1 ± 11.9

121

Tir 5mg

  

72/49

55.8 ± 10.4

121

Tir 10mg

  

63/58

52.9 ± 12.3

121

Tir 15mg

  

Frias, et al. (2020) [18]

12/14

56.0 ± 10.13

26

Placebo

12

HbA1c,Weight,AE, SAE

16/13

55.5 ± 8.54

29

Tir 15mg

  

Frias, et al. (2018) [19]

29/22

56.6 ± 8.9

51

Placebo

26

HbA1c,Weight,AE, SAE

34/21

57.9 ± 8.2

55

Tir 5mg

  

30/21

56.5 ± 9.9

51

Tir 10mg

  

22/31

56.0 ± 7.6

53

Tir 15mg

  

Heise, et al. (2022) [20]

21/7

60.4 ± 7.6

28

Placebo

28

Weight,AE, SAE

31/14

61.1 ± 7.1

45

Tir 15mg

  

Blonde, et al. (2020) [21]

58/42

56.0 ± 9.9

100

Placebo

26

HbA1c,Weight,AE, SAE

125/78

54.7 ± 10.1

203

Lir 1.8mg

  

Harder, et al. (2004) [22]

1/11

60.1 ± 6.7

12

Placebo

8

HbA1c,Weight

11/10

59.9 ± 11.0

21

Lir 0.6mg

  

Seino, et al. (2008) [23]

29/17

57.5 ± 8.7

46

Placebo

14

HbA1c,Weight

28/17

60 ± 7.0

45

Lir 0.6mg

  

Marre, et al. (2009) [24]

54/60

54.7 ± 10.0

114

Placebo

26

HbA1c,Weight, SAE

126/107

55.7 ± 9.9

233

Lir 0.6mg

  

102/126

57.7 ± 9.0

228

Lir 1.2mg

  

124/110

55.6 ± 10.0

234

Lir 1.8mg

  

Russell-Jones, et al. (2009) [25]

56/59

57.5 ± 9.6

115

Placebo

26

HbA1c,Weight,AE, SAE

132/100

57.6 ± 9.5

232

Lir 1.8mg

  

Yale, et al. (2017) [26]

41/28

64.3 ± 7.76

69

Placebo

52

HbA1c,Weight,AE, SAE

37/37

64.3 ± 8.49

74

Can 100mg

  

42/30

65.8 ± 7.88

72

Can 300mg

  

Kadowaki, et al. (2017) [27]

53/15

56.0 ± 9.5

68

Placebo

24

HbA1c,Weight,AE, SAE

54/16

58.4 ± 8.9

70

Can 100mg

  

Inagaki, et al. (2013) [28]

54/21

57.7 ± 11.0

75

Placebo

12

HbA1c,Weight,SBP,DBP,AE, SAE

52/22

57.7 ± 10.5

74

Can 100mg

  

49/27

57.0 ± 10.7

76

Can 200mg

  

55/20

57.1 ± 10.1

75

Can 300mg

  

Inagaki, et al. (2014) [29]

60/33

58.2 ± 11.0

93

Placebo

24

HbA1c,Weight,SBP,DBP,AE, SAE

60/33

58.4 ± 10.4

93

Can 100mg

  

72/16

57.4 ± 11.1

88

Can 200mg

  

Stenlof, et al. (2013) [30]

88/104

55.7 ± 10.9

192

Placebo

26

HbA1c,Weight,SBP,DBP,AE, SAE

81/114

55.1 ± 10.8

195

Can 100mg

  

89/108

55.3 ± 10.2

197

Can 300mg

  

Ji, et al. (2019) [31]

88/79

56.9 ± 9.0

167

Placebo

26

HbA1c,Weight,SBP,DBP,AE, SAE

95/65

56.1 ± 9.0

160

Ert 5mg

  

98/71

56.3 ± 9.3

169

Ert 15mg

  

Terra, et al. (2017) [32]

82/71

56.1 ± 10.9

153

Placebo

26

HbA1c,Weight,AE, SAE

89/67

56.8 ± 11.4

156

Ert 5mg

  

90/62

56.2 ± 10.8

152

Ert 15mg

  

Rosenstock, et al. (2018) [44]

98/111

56.5 ± 8.7

209

Placebo

26

HbA1c,Weight,AE, SAE

97/110

56.6 ± 8.1

207

Ert 5mg

  

93/112

56.9 ± 9.4

205

Ert 15mg

  

Dagogo-Jack S, et al. (2018) [33]

100/53

58.3 ± 9.2

153

Placebo

52

HbA1c,Weight,AE, SAE

81/75

59.2 ± 9.3

156

Ert 5mg

  

82/71

59.7 ± 8.6

153

Ert 15mg

  

Kadowaki, et al. (2014) [34]

80/29

58.7 ± 8.7

109

Placebo

12

HbA1c,Weight,SBP,DBP,AE, SAE

84/26

57.3 ± 11.2

110

Emp 5mg

  

77/32

57.9 ± 9.4

109

Emp 10mg

  

84/25

57.2 ± 9.7

109

Emp 25mg

  

Søfteland, et al. (2017) [35]

60/48

55.9 ± 9.7

108

Placebo

24

HbA1c,Weight,AE, SAE

66/43

54.3 ± 9.6

109

Emp 10mg

  

71/39

55.4 ± 9.9

110

Emp 25mg

  

Nishimura, et al. (2015) [36]

17/4

60.7 ± 10.8

21

Placebo

4

AE, SAE

14/6

64.8 ± 5.9

20

Emp 10mg

  

16/3

62.6 ± 7.8

19

Emp 25mg

  

Ferrannini, et al. (2013) [37]

45/37

58.0(28–80)

82

Placebo

12

HbA1c,Weight,AE

46/35

59.0(37–78)

81

Emp 5mg

  

40/41

58.0(30–76)

81

Emp 10mg

  

41/41

57.0(30–79)

82

Emp 25mg

  

Roden, et al. (2013) [38]

123/105

54.9 ± 10.9

228

Placebo

24

HbA1c,Weight,SBP,DBP,AE, SAE

142/82

56.2 ± 11.6

224

Emp 10mg

  

145/79

53.8 ± 11.6

224

Emp 25mg

  

Papadopoulou, et al. (2021) [39]

21/21

60.6 ± 9.4

42

Placebo

12

HbA1c,Weight

23/20

61.7 ± 6.7

43

Dap 10mg

  

Yang, et al. (2016) [40]

86/59

53.5 ± 9.2

145

Placebo

24

HbA1c,Weight,SBP,AE, SAE

67/80

53.1 ± 9.1

147

Dap 5mg

  

88/64

54.6 ± 9.5

152

Dap 10mg

  

Bailey, et al. (2010) [41]

76/67

53.7 ± 10.3

143

Placebo

24

HbA1c,Weight,AE, SAE

69/68

54.3 ± 9.4

137

Dap 5mg

  

77/58

52.7 ± 9.9

135

Dap 10mg

  

Weng, et al. (2021) [42]

93/68

55.3 ± 9.5

161

Placebo

24

HbA1c,Weight,SBP,DBP,AE, SAE

103/59

54.3 ± 9.5

162

Hen 5mg

  

101/59

54.7 ± 10.7

160

Hen 10mg

  

Lu, et al. (2021) [43]

100/51

52.4 ± 10.2

151

Placebo

24

HbA1c,Weight,SBP,DBP,AE, SAE

88/62

53.3 ± 9.6

150

Hen 5mg

  

115/36

52.2 ± 9.4

151

Hen 10mg

 Â